These outcomes led to an FDA priority review in February 2021 and to an ongoing phase III clinical trial comparing sotorasib with docetaxel for patients with KRAS c34G > T (p.G12C) mutant NSCLC (ClinicalTrials.gov NCT04303780). This evidence concerns the gene KRAS and non-small cell lung carcinoma.